TRPM7 Deficiency Protects Against Myocardial Ischemia-Reperfusion Injury by Regulating Intracell

Opportunity to reinterpret: TRPM7's role in ischemia-reperfusion injury through intracellular zinc homeostasis

• Ischemic heart disease remains a major mortality driver, with reperfusion necessary for tissue salvage but capable of causing additional cardiomyocyte death, contributing to infarct size.
• The study investigates TRPM7, a divalent cation–permeable channel-kinase that responds to oxidative stress and can mobilize Zn2+ from internal TRPM7–associated vesicles, in the context of myocardial I/R injury.

• Expression profiling identified TRPM7 upregulation in myocardium from patients with ischemic heart failure and in I/R-injured mice.
• Genetic models included global TRPM7 deficiency and cell-type–specific knockouts: cardiomyocyte-specific (cmTrpm7−/−) and fibroblast-specific (fibTrpm7−/−) mice to parse cell-origin effects on I/R injury.
• Functional and mechanistic analyses employed primary neonatal mouse cardiomyocytes, human induced pluripotent stem cell–derived cardiomyocytes, patch-clamp electrophysiology, Zn2+ imaging, and molecular biology approaches.
• A novel inducible TRPM7 channel-dead knock-in (TRPM7-E1047K) model was created to distinguish channel versus kinase contributions to injury.

• TRPM7 upregulation accompanies ischemic injury in human and murine myocardium.
• Global TRPM7 deficiency reduced infarct size and improved cardiac function following I/R injury.
• Cell-type dissection showed protection stemmed from TRPM7 loss in myocytes rather than fibroblasts, indicating a cardiomyocyte-autonomous protective mechanism mediated via suppression of pyroptosis.
• Mechanistically, Zn2+ release from intracellular TRPM7 vesicles during I/R activates a gasdermin-D–driven pore-forming pathway, fueling pyroptosis and cell death.
• Inhibition of membrane TRPM7 did not replicate the protective effect, reinforcing the centrality of intracellular TRPM7–dependent Zn2+ release rather than membrane channel activity alone.
• The channel function, not the kinase activity, underpins the exacerbation of I/R injury, as shown by comparisons with distinct knock-in models (channel-dead versus kinase-inactive TRPM7).

• Intracellular TRPM7–mediated Zn2+ release promotes cardiomyocyte death during I/R via apoptotic and pyroptotic pathways, with gasdermin-D–dependent pore formation as a downstream effector.
• The observed upregulation of TRPM7 in ischemic heart failure contexts positions TRPM7 as a potential therapeutic target for limiting I/R–related myocardial damage.
• The data emphasize that targeting the channel aspect of TRPM7, and specifically its intracellular Zn2+ handling, may offer a strategy distinct from approaches aimed at membrane channel inhibition.

• The report emphasizes mechanistic and preclinical findings; translation to human therapy requires further validation.
• While cell-type specificity was probed, broader systemic effects and long-term consequences of TRPM7 disruption remain to be clarified.

• How might selective inhibitors or modulators of intracellular TRPM7–Zn2+ release perform in diverse ischemic contexts?
• Could downstream blockade of gasdermin-D–mediated pore formation synergize with TRPM7-targeted strategies to further mitigate I/R injury?